Qiagen Obtains U.S. FDA Clearance For Gastrointestinal Panels On Fully Automated QIAstat-Dx Rise Syndromic Testing System

QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA))) today announced that the U.S. Food and Drug Administration (FDA) has cleared the use of all QIAstat-Dx® Gastrointestinal (GI) Panels on the QIAstat-Dx Rise automated syndromic testing system.

With this milestone, laboratories can run both QIAstat-Dx Respiratory and QIAstat-Dx GI panels on QIAstat-Dx Rise, the high-throughput version of the QIAstat-Dx system. Both versions support comprehensive syndromic testing with panels designed to detect multiple pathogens associated with similar symptoms in a single test, as well as targeted Mini panels that focus on a defined group of pathogens.